Australia's most trusted
source of pharma news
Thursday, 25 June 2026
Posted 25 June 2026 AM
Eli Lilly's once-weekly insulin injectable Efsitora will not reach Australia in the foreseeable future, with pricing yet again a sticking point for the world's most valuable pharma company.
The move ultimately leaves the market open to Novo Nordisk in Australia, which registered Awiqli, the first once-weekly injectable insulin, on the ARTG just over a year ago.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.